Letzte Änderung vom 10. Januar 2025
Dieser Artikel bietet einen Überblick über die aktuellen Änderungen der Medical Device Regulation (MDR). Wir haben alle hilfreichen Daten in das ColabON-Tool integriert. Dafür wurden über 100 Arbeitsstunden investiert. Dazu gehören die Verknüpfung mit harmonisierten Standards und die neuesten Änderungen, um sicherzustellen, dass Sie bestens vorbereitet sind.
Inhalt:
Offizieller Link zur konsolidierten MDR
Alle MDR-Änderungen
MDR-Änderung Zusammenfassung
Angereicherte und aktuelle MDR
Offizieller Link zur MDR Medizinprodukte Verordnung EU 2017/745 (Konsolidierte Version)
Änderungsliste der MDR - Medizinprodukte Verordnung EU 2017/745
Version: Name Of Amendment: Content
10/01/2025: M6 Amendment: UDI of Contact Lenses
In Part C of Annex VI to Regulation (EU) 2017/745 the following sections are added: 6.6. Highly individualised devices
09/07/2024: M5 Amendment: Gradual roll-out of Eudamed
14/02/2024: M4 14.2.2024 Fees and charges payable to the European Medicines Agency
Changes to Article 106 Provision of scientific, technical and clinical opinions and advice
Paragraph 14.
Article 120 - Transitional provisions
Article 122 - Repeal
11/03/2023: M2 Amendment: Frequency of complete re-assessments of notified bodies Article 44, paragraph 10
24/04/2020: M1 Amendment: Change of Application Dates: 26 May 2020’ is replaced by ‘26 May 2021’
05/05/2017: Initale Version
The following Corrigendums and were are part of the initial File
C1 Corrigendum
C2 Corrigendum
MDR ÄNDERUNG 10/01/2025 UDI für Kontaktlinsen
Effektiv: 09/11/2025
Quelle: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32023R2197
Die Änderung betrifft UDI für Kontaktlinsen:
..."In Part C of Annex VI to Regulation (EU) 2017/745 the following sections are added:
‘6.6. Highly individualised devices
6.6.1. Contact lenses
6.6.1.1. Standard contact lenses
A UDI-DI shall be assigned to standard contact lenses that have the same combination of contact lens design parameters, including at least base curve and diameter (“Master UDI-DI”).
In addition to the requirement laid down in Section 3.9, a new Master UDI-DI shall be required whenever there is a change in the combination of the design parameters referred to in the first paragraph.
6.6.1.2. Made to order contact lenses
A UDI-DI shall be assigned to made to order contact lenses that have the same combination of contact lens design parameters, including at least base curve and diameter (“Master UDI-DI”).
In addition to the requirement laid down in Section 3.9, a new Master UDI-DI shall be required whenever there is a change in the combination of the design parameters referred to in the first paragraph.’
Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 9 November 2025.
However, manufacturers may already before that date assign a Master UDI-DI in accordance with Regulation (EU) 2017/745 as amended by this Regulation."...Warum ist die angereicherte und konsolidierte MDR-Version hilfreich?
Eine konsolidierte MDR-Version ist das ColabON-Tool, das Herstellern hilft, sicherzustellen, dass alle notwendigen Anforderungen der Medizinprodukte-Verordnung (MDR) erfüllt werden. Diese Checkliste umfasst:
Die neuesten Änderungen der MDR
Herstellerangaben zu Anwendbarkeit und Rückverfolgbarkeit
Harmonisierungstexte für die harmonisierten Normen
Anforderungen an die technische Dokumentation
GSPRs (Allgemeine Sicherheits- und Leistungsanforderungen) mit Harmonisierungstexten
Die Verwendung einer angereicherten und aktualisierten MDR hilft Herstellern, ihre Compliance-Bemühungen zu optimieren und regulatorische Probleme zu vermeiden.
Was ist die MDR-Verordnung in Europa?
Die MDR-Verordnung in Europa, offiziell als Verordnung (EU) 2017/745 bekannt, regelt die Sicherheit, Leistung und Vermarktung von Medizinprodukten in der Europäischen Union. Sie ersetzt die frühere Medizinprodukterichtlinie (MDD) und führt strengere Regeln für klinische Bewertungen, die Überwachung nach dem Inverkehrbringen und die Rückverfolgbarkeit von Medizinprodukten ein. Die MDR gilt für alle in der EU verkauften Medizinprodukte und verlangt von Herstellern die Einhaltung strenger Anforderungen, um eine CE-Kennzeichnung für ihre Produkte zu erhalten.
Was ist der Unterschied zwischen EU-MDR und UK-MDR?
Der Unterschied zwischen der EU-MDR und der UK-MDR ergibt sich aus der regulatorischen Trennung nach dem Brexit. Die EU-MDR gilt für Medizinprodukte, die in der Europäischen Union vermarktet werden, während die UK-MDR die Medizinprodukte im Vereinigten Königreich regelt. Während die UK-MDR derzeit viele Anforderungen der EU-MDR widerspiegelt, hat das Vereinigte Königreich sein eigenes Kennzeichnungssystem (UKCA) eingeführt und könnte im Laufe der Zeit abweichende Vorschriften entwickeln, da es unabhängige Standards entwickelt.
Was sind die neuen Anforderungen der EU-MDR?
Die neuen Anforderungen der EU-MDR umfassen:
Strengere Prüfungen klinischer Bewertungen
Erhöhte Verpflichtungen zur Überwachung nach dem Inverkehrbringen
Einführung einer Unique Device Identification (UDI) zur Rückverfolgbarkeit
Strengere Anforderungen für Hochrisikoprodukte
Hersteller müssen außerdem sicherstellen, dass ihre technische Dokumentation umfassend ist und mit harmonisierten Normen übereinstimmt, um die Konformität mit den neuen MDR-Vorschriften nachzuweisen.
Auf welche Länder findet die MDR Anwendung?
Die MDR gilt in allen Ländern der Europäischen Union. Darüber hinaus übernehmen auch Nicht-EU-Länder wie die Schweiz, Norwegen, Island und Liechtenstein die MDR für Medizinprodukte, die in ihren Märkten angeboten werden. Hersteller, die in diesen Regionen Medizinprodukte verkaufen möchten, müssen die MDR-Anforderungen einhalten, um Sicherheit und regulatorische Konformität sicherzustellen.
M4 Amendments to Regulation (EU) 2017/745: gradual roll-out of Eudamed
Amendments to Regulation (EU) 2017/745
Regulation (EU) 2017/745 is amended as follows:
(1)
the following article is inserted:
‘Article 10a
Obligations in case of interruption or discontinuation of supply of certain devices
1. Where a manufacturer anticipates an interruption or a discontinuation of the supply of a device, other than a custom-made device, and where it is reasonably foreseeable that such interruption or discontinuation could result in serious harm or a risk of serious harm to patients or public health in one or more Member States, the manufacturer shall inform the competent authority of the Member State where it or its authorised representative is established, as well as the economic operators, health institutions and healthcare professionals to whom it directly supplies the device, of the anticipated interruption or discontinuation.
The information referred to in the first subparagraph shall, other than in exceptional circumstances, be provided at least 6 months before the anticipated interruption or discontinuation. The manufacturer shall specify the reasons for the interruption or discontinuation in the information provided to the competent authority.
2. The competent authority that has received the information referred to in paragraph 1 shall, without undue delay, inform the competent authorities of the other Member States and the Commission of the anticipated interruption or discontinuation.
3. The economic operators who have received the information from the manufacturer in accordance with paragraph 1 or from another economic operator in the supply chain shall, without undue delay, inform any other economic operators, health institutions and healthcare professionals to whom they directly supply the device, of the anticipated interruption or discontinuation.’
;
(2)
Article 34 is amended as follows:
(a)
paragraph 1 is replaced by the following:
‘1. The Commission shall, in collaboration with the MDCG, draw up the functional specifications for Eudamed. The Commission shall draw up a plan for the implementation of those specifications by 26 May 2018.’
;
(b)
paragraph 2 is replaced by the following:
‘2. The Commission shall inform the MDCG when, on the basis of independent audit reports, it has verified that one or more of the electronic systems referred to in Article 33(2) are functional and meet the functional specifications drawn up pursuant to paragraph 1 of this Article.’
;
(3)
in Article 78, paragraph 14 is replaced by the following:
‘14. All Member States shall be required to apply the procedure set out in this Article from the date corresponding to 5 years from the date of publication of the notice referred to in Article 34(3), informing that the electronic system referred to in Article 33(2), point (e), is functional and meets the functional specifications drawn up pursuant to Article 34(1).
Before the date set out in the first subparagraph of this paragraph and at the earliest 6 months from the date of publication of the notice referred to in that subparagraph, the procedure set out in this Article shall be applied only by those Member States in which the clinical investigation is to be conducted which have agreed to apply it.’
;
(4)
Article 120 is amended as follows:
(a)
paragraph 8 is deleted;
(b)
the following paragraph is added:
‘13. Article 10a shall also apply to devices referred to in paragraphs 3a and 3b of this Article.’
;
(5)
in Article 122, first paragraph, the first to fourth indents are replaced by the following:
‘—
Articles 8 and 10, Article 10b(1), points (b) and (c), and Article 10b(2) and (3) of Directive 90/385/EEC, Article 10, Article 14a(1), points (c) and (d), Article 14a(2) and (3) and Article 15 of Directive 93/42/EEC, and the obligations relating to vigilance and clinical investigations provided for in the corresponding Annexes to those Directives, which are repealed, as applicable, with effect from the date referred to in Article 123(3), point (d), of this Regulation in respect of the application of the obligations and requirements that relate to the electronic systems referred to in Article 33(2), points (e) and (f), respectively, of this Regulation;
—
Article 10a, Article 10b(1), point (a), and Article 11(5) of Directive 90/385/EEC, Article 14(1) and (2), Article 14a(1), points (a) and (b), and Article 16(5) of Directive 93/42/EEC, and the obligations relating to registration of devices and economic operators, and to certificate notifications, provided for in the corresponding Annexes to those Directives, which are repealed, as applicable, with effect from the date referred to in Article 123(3), point (d), of this Regulation in respect of the application of the obligations and requirements that relate to the electronic systems referred to in Article 33(2), points (a) to (d), respectively, of this Regulation;’
;
(6)
Article 123(3) is amended as follows:
(a)
point (d) is amended as follows:
(i)
the first subparagraph is amended as follows:
(1)
the introductory wording is replaced by the following:
‘without prejudice to the obligations of the Commission pursuant to Article 34, the obligations and requirements that relate to any of the electronic systems referred to in Article 33(2) shall apply from the date corresponding to 6 months from the date of publication of the notice referred to in Article 34(3), informing that the relevant electronic system is functional and meets the functional specifications drawn up pursuant to Article 34(1). The provisions referred to in the preceding sentence are:’
;
(2)
the following indent is inserted after the twelfth indent:
‘—
Article 56(5),’
;
(3)
the fourteenth indent is replaced by the following:
‘—
Article 78(1) to (13), without prejudice to Article 78(14),’
;
(ii)
the second subparagraph is replaced by the following:
‘Until the date of application of the provisions referred to in the first subparagraph of this point, the corresponding provisions of Directives 90/385/EEC and 93/42/EEC regarding information on vigilance reporting, clinical investigations, registration of devices and economic operators, and certificate notifications shall continue to apply;’
;
(b)
point (e) is replaced by the following:
‘(e)
no later than 12 months from the date of publication of the notice referred to in Article 34(3) in respect of the electronic system referred to in Article 33(2), points (a) and (b), manufacturers shall ensure that the information to be entered in Eudamed in accordance with Article 29 is entered in that electronic system, including regarding the following devices, provided that those devices are also placed on the market from 6 months from the date of publication of that notice:
(i)
devices, other than custom-made devices, for which the manufacturer has undertaken a conformity assessment in accordance with Article 52;
(ii)
devices, other than custom-made devices, placed on the market pursuant to Article 120(3), (3a) or (3b), unless the device, for which the manufacturer has undertaken a conformity assessment in accordance with Article 52, is already registered in Eudamed;’
;
(c)
the following points are inserted:
‘(ea)
no later than 18 months from the date of publication of the notice referred to in Article 34(3) in respect of the electronic system referred to in Article 33(2), point (d), notified bodies shall ensure that the information to be entered in Eudamed in accordance with Article 56(5) is entered in that electronic system, including regarding devices referred to in point (e)(i) of this paragraph; for those devices, only the latest relevant certificate and, where applicable, any subsequent decision taken by the notified body related to such certificate shall be entered;
(eb)
by way of derogation from point (d), first subparagraph, of this paragraph, the obligations to upload the summary of safety and clinical performance in accordance with Article 32(1) and to notify competent authorities in accordance with Article 55(1), through the electronic system referred in Article 33(2), point (d), shall apply to devices referred to in point (e) of this paragraph when the certificate is entered in Eudamed in accordance with point (ea) of this paragraph;
(ec)
without prejudice to point (d), first subparagraph, of this paragraph, when a manufacturer is to submit a PSUR in accordance with Article 86(2) of this Regulation, to report a serious incident or a field safety corrective action in accordance with Article 87 of this Regulation, or to submit a trend report in accordance with Article 88 of this Regulation through the electronic system referred to in Article 33(2), point (f), of this Regulation, it shall also register the device, which is the subject of the PSUR or the vigilance reporting, in the electronic system referred to in Article 33(2), points (a) and (b), of this Regulation, except if such device was placed on the market in accordance with Directive 90/385/EEC or 93/42/EEC;’
;
(d)
point (h) is deleted.
Article 2
Amendments to Regulation (EU) 2017/746
Regulation (EU) 2017/746 is amended as follows:
(1)
the following article is inserted:
‘Article 10a
Obligations in case of interruption or discontinuation of supply of certain devices
1. Where a manufacturer anticipates an interruption or a discontinuation of the supply of a device and where it is reasonably foreseeable that such interruption or discontinuation could result in serious harm or a risk of serious harm to patients or public health in one or more Member States, the manufacturer shall inform the competent authority of the Member State where it or its authorised representative is established, as well as the economic operators, health institutions and healthcare professionals to whom it directly supplies the device, of the anticipated interruption or discontinuation.
The information referred to in the first subparagraph shall, other than in exceptional circumstances, be provided at least 6 months before the anticipated interruption or discontinuation. The manufacturer shall specify the reasons for the interruption or discontinuation in the information provided to the competent authority.
2. The competent authority that has received the information referred to in paragraph 1 shall, without undue delay, inform the competent authorities of the other Member States and the Commission of the anticipated interruption or discontinuation.
3. The economic operators who have received the information from the manufacturer in accordance with paragraph 1 or from another economic operator in the supply chain shall, without undue delay, inform any other economic operators, health institutions and healthcare professionals to whom they directly supply the device of the anticipated interruption or discontinuation.’
;
(2)
in Article 74, paragraph 14 is replaced by the following:
‘14. All Member States shall be required to apply the procedure set out in this Article from the date corresponding to 5 years from the date of publication of the notice referred to in Article 34(3) of Regulation (EU) 2017/745, informing that the electronic system referred to in Article 30(2), point (e), of this Regulation is functional and meets the functional specifications drawn up pursuant to Article 34(1) of Regulation (EU) 2017/745.
Before the date set out in the first subparagraph of this paragraph and at the earliest 6 months from the date of publication of the notice referred to in that subparagraph, the procedure set out in this Article shall be applied only by those Member States in which the performance study is to be conducted which have agreed to apply it.’
;
(3)
Article 110 is amended as follows:
(a)
in paragraph 2, the second subparagraph is replaced by the following:
‘Certificates issued by notified bodies in accordance with Directive 98/79/EC from 25 May 2017 that were still valid on 26 May 2022 and that have not been withdrawn thereafter shall continue to remain valid after the end of the period indicated on the certificate until 31 December 2027. Certificates issued by notified bodies in accordance with that Directive from 25 May 2017 that were still valid on 26 May 2022 and that have expired before 9 July 2024 shall be considered to be valid until 31 December 2027 only if one of the following conditions is fulfilled:
(a)
before the date of expiry of the certificate, the manufacturer and a notified body have signed a written agreement in accordance with Section 4.3, second subparagraph, of Annex VII to this Regulation for the conformity assessment in respect of the device covered by the expired certificate or in respect of a device intended to substitute that device;
(b)
a competent authority of a Member State has granted a derogation from the applicable conformity assessment procedure in accordance with Article 54(1) of this Regulation or has required the manufacturer, in accordance with Article 92(1) of this Regulation, to carry out the applicable conformity assessment procedure.’
;
(b)
paragraph 3 is replaced by the following:
‘3. By way of derogation from Article 5 and provided the conditions set out in paragraph 3c of this Article are met, devices referred to in paragraphs 3a and 3b of this Article may be placed on the market or put into service until the dates set out in those paragraphs.’
;
(c)
the following paragraphs are inserted:
‘3a. Devices which have a certificate that was issued in accordance with Directive 98/79/EC and that is valid by virtue of paragraph 2 of this Article may be placed on the market or put into service until 31 December 2027.
3b. Devices for which the conformity assessment procedure pursuant to Directive 98/79/EC did not require the involvement of a notified body, for which a declaration of conformity was drawn up prior to 26 May 2022 in accordance with that Directive, and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body, may be placed on the market or put into service until the following dates:
(a)
31 December 2027, for class D devices;
(b)
31 December 2028, for class C devices;
(c)
31 December 2029, for class B devices and for class A devices placed on the market in sterile condition.
3c. Devices referred to in paragraphs 3a and 3b of this Article may be placed on the market or put into service until the dates referred to in those paragraphs only if the following conditions are met:
(a)
those devices continue to comply with Directive 98/79/EC;
(b)
there are no significant changes in the design and intended purpose;
(c)
the devices do not present an unacceptable risk to the health or safety of patients, users or other persons, or to other aspects of the protection of public health;
(d)
no later than 26 May 2025, the manufacturer has put in place a quality management system in accordance with Article 10(8);
(e)
the manufacturer or the authorised representative has lodged a formal application with a notified body in accordance with Section 4.3, first subparagraph, of Annex VII for conformity assessment in respect of a device referred to in paragraph 3a or 3b of this Article or in respect of a device intended to substitute that device, no later than:
(i)
26 May 2025, for devices referred to in paragraph 3a and paragraph 3b, point (a), of this Article;
(ii)
26 May 2026, for devices referred to in paragraph 3b, point (b), of this Article;
(iii)
26 May 2027, for devices referred to in paragraph 3b, point (c), of this Article;
(f)
the notified body and the manufacturer have signed a written agreement in accordance with Section 4.3, second subparagraph, of Annex VII no later than:
(i)
26 September 2025, for devices referred to in paragraph 3a and paragraph 3b, point (a), of this Article;
(ii)
26 September 2026, for devices referred to in paragraph 3b, point (b), of this Article;
(iii)
26 September 2027, for devices referred to in paragraph 3b, point (c), of this Article.
3d. By way of derogation from paragraph 3 of this Article, the requirements of this Regulation relating to post-market surveillance, market surveillance, vigilance, and to the registration of economic operators and of devices shall apply to devices referred to in paragraphs 3a and 3b of this Article, instead of the corresponding requirements in Directive 98/79/EC.
3e. Without prejudice to Chapter IV and paragraph 1 of this Article, the notified body that issued the certificate referred to in paragraph 3a of this Article shall continue to be responsible for the appropriate surveillance in respect of the applicable requirements relating to the devices it has certified, unless the manufacturer has agreed with a notified body designated in accordance with Article 38 that the latter shall carry out such surveillance.
No later than 26 September 2025, the notified body that has signed the written agreement referred to in paragraph 3c, point (f), of this Article shall become responsible for the surveillance in respect of the devices covered by the written agreement. Where the written agreement covers a device intended to substitute a device which has a certificate that was issued in accordance with Directive 98/79/EC, the surveillance shall be conducted in respect of the device that is being substituted.
The arrangements for the transfer of the surveillance from the notified body that issued the certificate to the notified body designated in accordance with Article 38 shall be clearly defined in an agreement between the manufacturer and the notified body designated in accordance with Article 38 and, where practicable, the notified body that issued the certificate. The notified body designated in accordance with Article 38 shall not be responsible for conformity assessment activities carried out by the notified body that issued the certificate.’
;
(d)
paragraph 8 is deleted;
(e)
the following paragraph is added:
‘11. Article 10a shall also apply to devices referred to in paragraphs 3a and 3b of this Article.’
;
(4)
Article 112 is amended as follows:
(a)
the first paragraph is replaced by the following:
‘Without prejudice to Article 110(3) to (4) of this Regulation, and without prejudice to the obligations of the Member States and manufacturers as regards vigilance and to the obligations of manufacturers as regards the making available of documentation, under Directive 98/79/EC, that Directive is repealed with effect from 26 May 2022, with the exception of:
(a)
Article 11, Article 12(1), point (c), and Article 12(2) and (3) of Directive 98/79/EC, and the obligations relating to vigilance and performance studies provided for in the corresponding Annexes to that Directive, which are repealed, as applicable, with effect from the date referred to in Article 113(3), point (f), of this Regulation in respect of the application of the obligations and requirements that relate to the electronic systems referred to in Article 30(2), points (e) and (f), respectively, of this Regulation;
(b)
Article 10, Article 12(1), points (a) and (b), and Article 15(5) of Directive 98/79/EC, and the obligations relating to registration of devices and economic operators, and certificate notifications provided for in the corresponding Annexes to that Directive, which are repealed, as applicable, with effect from the date referred to in Article 113(3), point (f), of this Regulation in respect of the application of the obligations and requirements that relate to the electronic systems referred to in Article 30(2), points (a) to (d), respectively, of this Regulation.’
;
(b)
the second paragraph is replaced by the following:
‘As regards the devices referred to in Article 110(3) to (4) of this Regulation, Directive 98/79/EC shall continue to apply to the extent necessary for the application of those paragraphs.’
;
(5)
Article 113(3) is amended as follows:
(a)
point (a) is deleted;
(b)
point (f) is amended as follows:
(i)
the first subparagraph is amended as follows:
(1)
the introductory wording is replaced by the following:
‘without prejudice to the obligations of the Commission pursuant to Article 34 of Regulation (EU) 2017/745, the obligations and requirements that relate to any of the electronic systems referred to in Article 30(2) of this Regulation shall apply from the date corresponding to 6 months from the date of publication of the notice referred to in Article 34(3) of Regulation (EU) 2017/745, informing that the relevant electronic system is functional and meets the functional specifications drawn up pursuant to Article 34(1) of that Regulation. The provisions referred to in the preceding sentence are:’
;
(2)
the following indent is inserted after the tenth indent:
‘—
Article 51(5),’
;
(3)
the twelfth indent is replaced by the following:
‘—
Article 74(1) to (13), without prejudice to Article 74(14),’
;
(4)
the final indent is replaced by the following:
‘—
Article 110(3d).’
;
(ii)
the second subparagraph is replaced by the following:
‘Until the date of application of the provisions referred to in the first subparagraph of this point, the corresponding provisions of Directive 98/79/EC regarding information on vigilance reporting, performance studies, registration of devices and economic operators, and certificate notifications shall continue to apply.’
;
(c)
the following points are inserted:
‘(fa)
no later than 6 months from the date set out in point (f), first subparagraph, of this paragraph, manufacturers shall ensure that the information to be entered in Eudamed in accordance with Article 26 is entered in the electronic system referred to in Article 30(2), points (a) and (b), including regarding the following devices, provided that those devices are also placed on the market from the date set out in point (f), first subparagraph, of this paragraph:
(i)
devices for which the manufacturer has undertaken a conformity assessment in accordance with Article 48;
(ii)
devices placed on the market pursuant to Article 110(3), (3a) or (3b), unless the device, for which the manufacturer has undertaken a conformity assessment in accordance with Article 48, is already registered in Eudamed;
(fb)
no later than 12 months from the date set out in point (f), first subparagraph, of this paragraph, notified bodies shall ensure that the information to be entered in Eudamed in accordance with Article 51(5) is entered in the electronic system referred to in Article 30(2), point (d), including regarding devices referred to in point (fa)(i) of this paragraph; for those devices, only the latest relevant certificate and, where applicable, any subsequent decision taken by the notified body related to such certificate shall be entered;
(fc)
by way of derogation from point (f), first subparagraph, of this paragraph, the obligations to upload the summary of safety and performance in accordance with Article 29(1) and to notify competent authorities in accordance with Article 50(1), through the electronic system referred in Article 30(2), point (d), shall apply to devices referred to in point (fa) of this paragraph when the certificate is entered in Eudamed in accordance with point (fb) of this paragraph;
(fd)
without prejudice to point (f), first subparagraph, of this paragraph, when a manufacturer is to submit a PSUR in accordance with Article 81(2) of this Regulation, to report a serious incident or a field safety corrective action in accordance with Article 82 of this Regulation, or to submit a trend report in accordance with Article 83 of this Regulation through the electronic system referred to in Article 30(2), point (f), of this Regulation, it shall also register the device, which is the subject of the PSUR or the vigilance reporting, in the electronic system referred to in Article 30(2), points (a) and (b), of this Regulation, except if such device was placed on the market in accordance with Directive 98/79/EC;’
;
(d)
point (g) is deleted;
(e)
in point (j), the date ‘26 May 2028’ is replaced by ‘31 December 2030’.
Article 3
Entry into force
This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.
Article 1, point (1), and Article 2, point (1), shall apply from 10 January 2025.
Comentários